SGC707

PRMT3 inhibitor CAS# 1687736-54-4

SGC707

Catalog No. BCC6543----Order now to get a substantial discount!

Product Name & Size Price Stock
SGC707: 5mg $46 In Stock
SGC707: 10mg Please Inquire In Stock
SGC707: 20mg Please Inquire Please Inquire
SGC707: 50mg Please Inquire Please Inquire
SGC707: 100mg Please Inquire Please Inquire
SGC707: 200mg Please Inquire Please Inquire
SGC707: 500mg Please Inquire Please Inquire
SGC707: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of SGC707

Number of papers citing our products

Chemical structure

SGC707

3D structure

Chemical Properties of SGC707

Cas No. 1687736-54-4 SDF Download SDF
PubChem ID 90642938 Appearance Powder
Formula C16H18N4O2 M.Wt 298.34
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (335.19 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 1-isoquinolin-6-yl-3-(2-oxo-2-pyrrolidin-1-ylethyl)urea
SMILES C1CCN(C1)C(=O)CNC(=O)NC2=CC3=C(C=C2)C=NC=C3
Standard InChIKey DMIDPTCQPIJYFE-UHFFFAOYSA-N
Standard InChI InChI=1S/C16H18N4O2/c21-15(20-7-1-2-8-20)11-18-16(22)19-14-4-3-13-10-17-6-5-12(13)9-14/h3-6,9-10H,1-2,7-8,11H2,(H2,18,19,22)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

SGC707 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

SGC707 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of SGC707

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.3519 mL 16.7594 mL 33.5188 mL 67.0376 mL 83.797 mL
5 mM 0.6704 mL 3.3519 mL 6.7038 mL 13.4075 mL 16.7594 mL
10 mM 0.3352 mL 1.6759 mL 3.3519 mL 6.7038 mL 8.3797 mL
50 mM 0.067 mL 0.3352 mL 0.6704 mL 1.3408 mL 1.6759 mL
100 mM 0.0335 mL 0.1676 mL 0.3352 mL 0.6704 mL 0.838 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on SGC707

SGC707 is a selective, potent, low molecular weight (MW = 298) and cell-active allosteric inhibitor of protein arginine N-methyltransferase 3 (PRMT3). PRMT3, one of the four type I protein arginine N-methyltransferases, has been implicated in ribosomal biosynthesis via catalyzing the formation of asymmetric (type I) mono- and dimethylarginine. PRMT3 has also been involved in cancer via interaction with the DAL-1 tumor suppressor protein [1]. SGC707 inhibits the activity of PRMT3 by targeting the dimerization interface of PRMT3[2].

In vitro: The IC50 and KD value of SGC707 against PRMT3was 31 ± 2 nM and 53 ± 2 nM respectively. SGC707 showed an outstanding selectivity for PRMT3 against 31 other methyltransferases and a broad range of 250 non-epigenetic targets, G protein-coupled receptors (GPCRs), ion channels, and transporters. The residence time of SGC707 was 9.7 min. In both HEK293 and A549 cells, SGC707 stabilized PRMT3 with EC50 values of 1.3 μM and 1.6 μM, respectively. SGC707 treatment at high concentrations 50 and 100 mM for 72 h lead to some toxicity [1].

In vivo: In CD-1 male mice, intraperitoneal injection of SGC707 at 30 mg/kg for over 6 h showed good plasma exposure with the peak plasma level of 38 ?M. After injection 6 h, the plasma level of SGC707 decreased to 208 nM. The half-life of SGC707 was about 1 h. The 30 mg/kg dose was well tolerated in the tested mouse model [1].

References:
Kaniskan H ?, Szewczyk M M, Yu Z, et al.  A Potent, Selective and Cell‐Active Allosteric Inhibitor of Protein Arginine Methyltransferase 3 (PRMT3)[J]. Angewandte Chemie International Edition, 2015, 54(17): 5166-5170.
Luo M.  Inhibitors of protein methyltransferases as chemical tools[J]. Epigenomics, 2015, 7(8): 1327-1338.

Featured Products
New Products
 

References on SGC707

Inhibition of PRMT3 activity reduces hepatic steatosis without altering atherosclerosis susceptibility in apoE knockout mice.[Pubmed:30776415]

Biochim Biophys Acta Mol Basis Dis. 2019 Feb 15. pii: S0925-4439(19)30064-X.

The nuclear receptor liver X receptor (LXR) impacts on cholesterol metabolism as well as hepatic lipogenesis via transcriptional regulation. It is proposed that inhibition of the protein arginine methyltransferase 3 (PRMT3) uncouples these two transcriptional pathways in vivo by acting as a specific lipogenic coactivator of LXR. Here we validated the hypothesis that treatment with the allosteric PRMT3 inhibitor SGC707 will diminish the hepatic steatosis extent, while leaving global cholesterol metabolism, important in cholesterol-driven pathologies like atherosclerosis, untouched. For this purpose, 12-week old hyperlipidemic apolipoprotein E knockout mice were fed a Western-type diet for six weeks to induce both hepatic steatosis and atherosclerosis. The mice received 3 intraperitoneal injections with SGC707 or solvent control per week. Mice chronically treated with SGC707 developed less severe hepatic steatosis as exemplified by the 51% reduced (P<0.05) liver triglyceride levels. In contrast, the extent of in vivo macrophage foam cell formation and aortic root atherosclerosis was not affected by SGC707 treatment. Interestingly, SGC707-treated mice gained 94% less body weight (P<0.05), which was paralleled by changes in white adipose tissue morphology, i.e. reduction in adipocyte size and browning. In conclusion, we have shown that through PRMT3 inhibitor treatment specific functions of LXR involved in respectively the development of fatty liver disease and atherosclerosis can be uncoupled, resulting in an overall diminished hepatic steatosis extent without a negative impact on atherosclerosis susceptibility. As such, our studies highlight that PRMT3 inhibition may constitute a novel therapeutic approach to limit the development of fatty liver disease in humans.

Inhibition of protein arginine methyltransferase 3 activity selectively impairs liver X receptor-driven transcription of hepatic lipogenic genes in vivo.[Pubmed:29774529]

Br J Pharmacol. 2018 Aug;175(15):3175-3183.

BACKGROUND AND PURPOSE: Agonists for the liver X receptor (LXR) are considered promising therapeutic moieties in cholesterol-driven diseases by promoting cellular cholesterol efflux pathways. However, current clinical application of these agents is hampered by concomitant LXR-induced activation of a lipogenic transcriptional network, leading to hepatic steatosis. Recent studies have suggested that protein arginine methyltransferase 3 (PRMT3) may act as a selective co-activator of LXR activity. Here, we verified the hypothesis that PRMT3 inhibition selectively disrupts the ability of LXR to stimulate lipogenesis while maintaining its capacity to modulate macrophage cholesterol homeostasis. EXPERIMENTAL APPROACH: A combination of the LXR agonist T0901317 and palm oil was administered to C57BL/6 mice to maximally stimulate LXR and PRMT3 activity. PRMT3 activity was inhibited using the allosteric inhibitor SGC707. KEY RESULTS: Treatment with SGC707 did not negatively influence the T0901317/palm oil-induced up-regulation of the cholesterol efflux ATP-binding cassette transporter genes, ABCA1 and ABCG1, in peritoneal cells. In contrast, SGC707 treatment was associated with a significant decrease in the hepatic expression of the lipogenic gene fatty acid synthase (-64%). A similar trend was observed for stearoyl-coenzyme A desaturase and acetyl CoA carboxylase expression (-43%; -56%). This obstruction of lipogenic gene transcription coincided with a significant 2.3-fold decrease in liver triglyceride content as compared with the T0901317 and palm oil-treated control group. CONCLUSION AND IMPLICATIONS: We showed that inhibition of PRMT3 activity by SGC707 treatment selectively impairs LXR-driven transcription of hepatic lipogenic genes, while the positive effect of LXR stimulation on macrophage cholesterol efflux pathways is maintained.

A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3).[Pubmed:25728001]

Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70.

PRMT3 catalyzes the asymmetric dimethylation of arginine residues of various proteins. It is essential for maturation of ribosomes, may have a role in lipogenesis, and is implicated in several diseases. A potent, selective, and cell-active PRMT3 inhibitor would be a valuable tool for further investigating PRMT3 biology. Here we report the discovery of the first PRMT3 chemical probe, SGC707, by structure-based optimization of the allosteric PRMT3 inhibitors we reported previously, and thorough characterization of this probe in biochemical, biophysical, and cellular assays. SGC707 is a potent PRMT3 inhibitor (IC50 =31+/-2 nM, KD =53+/-2 nM) with outstanding selectivity (selective against 31 other methyltransferases and more than 250 non-epigenetic targets). The mechanism of action studies and crystal structure of the PRMT3-SGC707 complex confirm the allosteric inhibition mode. Importantly, SGC707 engages PRMT3 and potently inhibits its methyltransferase activity in cells. It is also bioavailable and suitable for animal studies. This well-characterized chemical probe is an excellent tool to further study the role of PRMT3 in health and disease.

Description

SGC707 is a first-in-class PRMT3 chemical probe which is a potent, selective, and cell-active allosteric inhibitor of PRMT3 with IC50 of 31 nM.

Keywords:

SGC707,1687736-54-4,Natural Products,Histone Methyltransferase, buy SGC707 , SGC707 supplier , purchase SGC707 , SGC707 cost , SGC707 manufacturer , order SGC707 , high purity SGC707

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: